Latanoprost is a prescription medication for the treatment of glaucoma. One of the side effect is it causes chronic dry eyes. If you take Latanoprost for glaucoma, we highly recommend that you take TheraLife Eye capsules to treat your dry eyes for better outcome.
Powerful Dry Eye Relief for People with Glaucoma
The best treatment to relief dry eyes for people with Glaucoma with TheraLife. Clinically Proven. Get Help Now!
Introduction
Latanoprost can also be purchased over-the-counter. It is not recommended to use latanoprost if you don’t have a prescription for it. It is possible to be allergic if you take it without a prescription. Topical solution of 50 ug/mL. One drop contains 1.5 uls of the medication. The nonmedicinal ingredients include sodium chloride, dibasic sodium phosphate, and momobasic sodium phosphate. As a preservative, benzalkonium phosphate is used.
Daily Glaucoma Treatment
People with glaucoma need to use latanoprost daily. If you stop using them, your vision can worsen. You must take the medication within six weeks. If you are taking it on a daily basis, you must follow the directions of your doctor. You should not use latanoprost if you have an eye infection or have just had surgery.
Consulting Your Doctor About Glaucoma
You should also consult a doctor if you have a history of glaucoma. This is a condition where the optic nerve is damaged leading to vision loss. Ocular hypertension also increases the likelihood of developing the condition. In these cases, latanoprost eye drops will help control the pressure and prevent further damage to the eye. If you take the medicine as directed, you should begin to see results.
Risks and Benefits of Latanoprost
Before taking latanoprost it is important that patients discuss the risks and benefits with their doctors. It may cause shortness of breath and other asthma symptoms. If you have asthma, talk with your doctor about any special monitoring that you need to be aware of while you are taking latanoprost. You should talk to your doctor if there are any questions. It can impact your health and your ability to use your medicine.
Latanoprost belongs the prostaglandin-analogues class of medications. This drug lowers the pressure in the eye. It regulates the flow fluid in the eyes. It prevents blindness for people with open-angle or chronic angle-closure, glaucoma. The medicine is usually taken two times daily. Depending on how severe the problem is, the medication can be used for up to four months.
Latanoprost is not recommended to be used more than once a day. It should not be used on the eye without washing the face thoroughly and using the prescribed drops. Incorrect application of the medication can lead to infection in the eye. Besides this, patients must be careful when applying it. It can also cause dark eyes. Its half-life is 20 minutes, which makes it a short-lived medication.
Combining latanoprost with timolol is more effective than either one alone, according to research. In addition, it can be administered alongside other anti-glaucoma medications. The drug is generally well tolerated and causes minimal side effects. It should be taken at least once a day. However, it is not recommended to be taken by people with eyelid anomalies.
While latanoprost might make your eyes look darker, it doesn’t affect the colour of your eyes. This side effect can be severe so you should discontinue using latanoprost immediately and consult your doctor. If the problem is not serious, a doctor may prescribe latanoprost for eye drops. These side effects may occur. If you have any one of these conditions, your doctor will tell you.
Latanoprost is an ophthalmic drug that reduces pressure in the eye. It was approved by the FDA in 1996, but it is not approved for the treatment of glaucoma. Its main purpose is to prevent glaucoma from worsening. It is a prescription medication and should not be used if your contact lenses are worn. Its side effects are minimal.
Studies on latanoprost showed that it is well tolerated by animals. Although there are no known serious side effects, a high-dose of the drug in humans can cause respiratory problems. A veterinary doctor will inspect your pet’s eyes and prevent any complications. You should immediately stop giving latanoprost to your pet if it causes side effects. Contact your veterinarian immediately if you have any history of the condition.
Frequently Asked Questions
Can glaucoma eye drops cause dry eyes?
How do you treat dry eyes from glaucoma?
What are the disadvantages of latanoprost?
- Change in eye colour. Talk to your doctor before you start using latanoprost if you’re worried about this. …
- Red and itchy eyelids, irritated eye and eye pain. …
- Inflamed eyelid. …
- Eye infection (conjunctivitis) …
- Changes to your eyelashes (growing longer and thicker) …
- Sensitivity to light (photophobia)
Can latanoprost cause dry eyes?
Conclusion
Latanoprost, sold under the brand name Xalatan among others, is a medication used to treat increased pressure inside the eye – called Glaucoma This includes ocular hypertension and open angle glaucoma. applied as eye drops to the eyes. Onset of effects is usually within four hours, and they last for up to a day.
Common side effects include blurry vision, redness of the eye, itchiness, and darkening of the iris. Latanoprost is in the prostaglandin analogue family of medications. It works by increasing the outflow of aqueous fluid from the eyes through the uveoscleral tract.
This medication does cause ocular surface changes that result in chronic dry eyes. Consult with TheraLife for long lasting relief of dry eyes. Avoid cornea damage and get life back on track.
References
Quigley HA . Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80 (5): 389–393.
Quigley HA, Broman AT . The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90 (3): 262–267.
Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT . The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands. The Rotterdam Study. Ophthalmology 1994; 101 (11): 1851–1855.
Friedman DS, Wolfs RC, O’Colmain BJ, Klein BE, Taylor HR, West S et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004; 122 (4): 532–538.
Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D . Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci 2006; 47 (10): 4254–4261.
Leske MC, Connell AM, Schachat AP, Hyman L . The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol 1994; 112 (6): 821–829.
Lee DA, Higginbotham EJ . Glaucoma and its treatment: a review. Am J Health Syst Pharm 2005; 62 (7): 691–699.
Baudouin C, Renard JP, Nordmann JP, Denis P, Lachkar Y, Sellem E et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol 2013; 23 (1): 47–54.
Skalicky SE, Goldberg I, McCluskey P . Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2012; 153 (1): 1–9 e2.
Paletta Guedes RA, Paletta Guedes VM, Freitas SM, Chaoubah A . Quality of life of medically versus surgically treated glaucoma patients. J Glaucoma 2012; 22: 369–373.
Noecker R . Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18 (5): 205–215.
Wilson WS, Duncan AJ, Jay JL . Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol 1975; 59 (11): 667–669.
Lemp MA, Baudouin C, Baum J, Dogru M, Foulks GN, Kinoshita S et al. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5 (2): 75–92.
Pisella PJ, Pouliquen P, Baudouin C . Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86 (4): 418–423.
Gayton JL, Van Der Karr M, Sanders V . Combined cataract and glaucoma surgery: trabeculectomy versus endoscopic laser cycloablation. J Cataract Refract Surg 1999; 25 (9): 1214–1219.
Baudouin C . Ocular surface and external filtration surgery: mutual relationships. Dev Ophthalmol 2012; 50: 64–78.
Versura P, Profazio V, Campos EC . Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases. Curr Eye Res 2010; 35 (7): 553–564.
Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A . Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci 2006; 47 (10): 4309–4315.
Lemp MA, Bron AJ, Baudouin C, Benitez Del Castillo JM, Geffen D, Tauber J et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011; 151 (5): 792–798 e1.
Sullivan BD, Whitmer D, Nichols KK, Tomlinson A, Foulks GN, Geerling G et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci 2010; 51 (12): 6125–6130.
Li DQ, Chen Z, Song XJ, Luo L, Pflugfelder SC . Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004; 45 (12): 4302–4311.
Labbe A, Terry O, Brasnu E, Van Went C, Baudouin C . Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea 2012; 31 (9): 994–999.
Januleviciene I, Derkac I, Grybauskiene L, Paulauskaite R, Gromnickaite R, Kuzmiene L . Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol 2012; 6: 103–109.
Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC . Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 2010; 29 (6): 618–621.
Arici MK, Arici DS, Topalkara A, Guler C . Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Experiment Ophthalmol 2000; 28 (2): 113–117.
Kuppens EV, Stolwijk TR, de Keizer RJ, van Best JA . Basal tear turnover and topical timolol in glaucoma patients and healthy controls by fluorophotometry. Invest Ophthalmol Vis Sci 1992; 33 (12): 3442–3448.
Herreras JM, Pastor JC, Calonge M, Asensio VM . Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992; 99 (7): 1082–1088.
Schaumberg DA, Gulati A, Mathers WD, Clinch T, Lemp MA, Nelson JD et al. Development and validation of a short global dry eye symptom index. Ocul Surf 2007; 5 (1): 50–57.
Sullivan BD, Crews LA, Messmer EM, Foulks GN, Nichols KK, Baenninger P et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol 2012 epub ahead of print 28 December 2012; doi:10.1111/aos.12012.
Khanal S, Millar TJ . Barriers to clinical uptake of tear osmolarity measurements. Br J Ophthalmol 2012; 96 (3): 341–344.
Sullivan BD, Crews LA, Sonmez B, de la Paz MF, Comert E, Charoenrook V et al. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management. Cornea 2012; 31 (9): 1000–1008.
Farris RL . Tear osmolarity—a new gold standard? Adv Exp Med Biol 1994; 350: 495–503.
Chen W, Li Z, Hu J, Zhang Z, Chen L, Chen Y et al. Corneal alternations induced by topical application of benzalkonium chloride in rabbit. PLoS One 2011; 6 (10): e26103.
Palmberg P . Surgery for complications. In Albert DM (eds) Ophthalmic Surgery: Principles and Techniques. Blackwell Science: Malden, MA, 1999 pp 176–191.
Budenz DL, Hoffman K, Zacchei A . Glaucoma filtering bleb dysesthesia. Am J Ophthalmol 2001; 131 (5): 626–630.
Fuentes-Paez G, Herreras JM, Cordero Y, Almaraz A, Gonzalez MJ, Calonge M . Lack of concordance between dry eye syndrome questionnaires and diagnostic tests. Arch Soc Esp Oftalmol 2011; 86 (1): 3–7.
Moore JE, Graham JE, Goodall EA, Dartt DA, Leccisotti A, McGilligan VE et al. Concordance between common dry eye diagnostic tests. Br J Ophthalmol 2009; 93 (1): 66–72.
Viso E, Rodriguez-Ares MT, Abelenda D, Oubina B, Gude F . Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci 2012; 53 (6): 2601–2606.
Neves Mendes CR, Hida RY, Kasahara N . Ocular surface changes in eyes with glaucoma filtering blebs. Curr Eye Res 2012; 37 (4): 309–311.
Soong HK, Quigley HA . Dellen associated with filtering blebs. Arch Ophthalmol 1983; 101 (3): 385–387.
Coppens G, Maudgal P . Corneal complications of intraoperative mitomycin C in glaucoma surgery. Bull Soc Belge Ophtalmol 2010; 314: 19–23.
Hau S, Barton K . Corneal complications of glaucoma surgery. Curr Opin Ophthalmol 2009; 20 (2): 131–136.
Sauder G, Jonas JB . Limbal stem cell deficiency after subconjunctival mitomycin C injection for trabeculectomy. Am J Ophthalmol 2006; 141 (6): 1129–1130.
Dua HS, Saini JS, Azuara-Blanco A, Gupta P . Limbal stem cell deficiency: concept, aetiology, clinical presentation, diagnosis and management. Indian J Ophthalmol 2000; 48 (2): 83–92.
Wilson SE, Netto M, Ambrosio R Jr. . Corneal cells: chatty in development, homeostasis, wound healing, and disease. Am J Ophthalmol 2003; 136 (3): 530–536.
Shimazaki J, Hanada K, Yagi Y, Yamagami J, Ishioka M, Shimmura S et al. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone. Br J Ophthalmol 2000; 84 (11): 1250–1254.
Leung EW, Medeiros FA, Weinreb RN . Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008; 17 (5): 350–355.
Yalvac IS, Gedikoglu G, Karagoz Y, Akgun U, Nurozler A, Koc F et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand 1995; 73 (3): 246–248.
Smith JA, Albeitz J, Begley C, Caffery B, Nichols K, Schaumberg D, Schein O . The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5 (2): 93–107.
Pflugfelder SC, Geerling G, Kinoshita S, Lemp MA, McCulley J, Nelson D et al. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007 5 (2): 163–178.
Thygesen J, Aaen K, Theodorsen F, Kessing SV, Prause JU . Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand 2000; 78 (1): 37–44.
Costagliola C, Prete AD, Incorvaia C, Fusco R, Parmeggiani F, Di Giovanni A . Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol 2001; 239 (11): 809–814.
Kulkarni SV, Damji KF, Buys YM . Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency. Patient Prefer Adherence 2008; 2: 303–314.
Bloch S, Rosenthal AR, Friedman L, Caldarolla P . Patient compliance in glaucoma. Br J Ophthalmol 1977; 61 (8): 531–534.
Pisella PJ, Fillacier K, Elena PP, Debbasch C, Baudouin C . Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res 2000; 32 (1): 3–8.
